...
首页> 外文期刊>Clinics and research in hepatology and gastroenterology >Clinicoradiologic characteristics and outcomes of metastatic cancer to the pancreas and double primary pancreatic cancer
【24h】

Clinicoradiologic characteristics and outcomes of metastatic cancer to the pancreas and double primary pancreatic cancer

机译:胰腺癌和双原发性胰腺癌的转移性癌的临床放射学特征和预后

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objectives: The goal of this study was to identify clinicoradiologic characteristics to distinguish metastatic cancer to the pancreas (MCP) from double primary pancreatic cancer (DPPC). Methods: From 2000 to 2011, we retrospectively identified MCP and DPPC patients among patients with histories of other primary malignancies. Results: A total of 94 patients with histories of other primary malignancies were histologically confirmed to have pancreatic cancer. Among them, 34 patients had MCP and 60 patients had DPPC, which were ductal adenocarcinomas. The kidney was the most common primary cancer site that metastasized to the pancreas (12, 35.3%). In the DPPC group, the stomach was the most common primary cancer site (11, 18.3%). There were 21 patients (61.8%) with metachronous pancreatic cancer in the MCP group and 29 (48.3%) in the DPPC group (P= 0.210). Among the metachronous pancreatic cancer patients, the disease-free interval was 88.3. months in the MCP group, and 49.6. months in the DPPC group (P= 0.062). The number of the patients who showed elevated CA 19-9 levels was higher in the DPPC group than in the MCP group (39 (65%) vs. 9 (26.5%); P= 0.001). Total bilirubin (P= 0.006) and fasting plasma glucose (P= 0.050) were also higher in the DPPC group. The numbers of patients who showed pancreatic duct dilatation (P= 0.002) and pancreatic atrophy (P= 0.008) on radiographs were meaningfully higher in the DPPC group than in the MCP group. On the other hand, the numbers of patients who showed well demarcated tumor margin (P< 0.000), tumor necrosis (P= 0.002), enhancement (P= 0.005) and distant metastasis (P= 0.028) were significantly higher in the MCP group than in the DPPC group. We evaluated differences in survival between the two groups. The median survival time in the MCP group (55. months) was significantly longer than that in the DPPC group (20. months). Conclusions: Other than elevated levels of CA 19-9, total bilirubin and fasting glucose, radiologic findings were the most reliable factors for distinguishing the MCP from the DPPC.
机译:目的:本研究的目的是确定临床放射学特征,以区分转移性胰腺癌(MCP)和双重原发性胰腺癌(DPPC)。方法:从2000年至2011年,我们在其他原发性恶性肿瘤病史中回顾性分析了MCP和DPPC患者。结果:总共94例具有其他原发性恶性肿瘤病史的患者在组织学上被证实患有胰腺癌。其中,MCP患者34例,DPPC患者60例,均为导管腺癌。肾脏是最常见的转移到胰腺的原发癌部位(12,35.3%)。在DPPC组中,胃是最常见的原发癌部位(11,18.3%)。 MCP组有21例(61.8%)异时性胰腺癌,DPPC组有29例(48.3%)(P = 0.210)。在异时胰腺癌患者中,无病间隔为88.3。 “ MCP”组中的第二个月和49.6。 DPPC组中的月数(P = 0.062)。 DPPC组中CA 19-9水平升高的患者人数比MCP组中高(39(65%)对9(26.5%); P = 0.001)。 DPPC组的总胆红素(P = 0.006)和空腹血糖(P = 0.050)也较高。 X线片显示胰腺导管扩张(P = 0.002)和胰腺萎缩(P = 0.008)的患者人数显着高于DPC组。另一方面,MCP组表现出良好界限的肿瘤切缘(P <0.000),肿瘤坏死(P = 0.002),增强(P = 0.005)和远处转移(P = 0.028)的患者数量明显增加。比DPPC组中的要多。我们评估了两组之间的生存差异。 MCP组的中位生存时间(55.个月)显着长于DPPC组的中位生存时间(20.个月)。结论:除了CA 19-9水平升高,总胆红素和空腹血糖升高外,放射学检查结果是区分MCP和DPPC的最可靠因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号